89bio, Inc. (ETNB )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol ETNB
- Company 89bio, Inc.
- Price $10.75
- Changes Percentage 15.72
- Change 1.46
- Day Low $9.38
- Day High $10.91
- Year High $16.63
- Year Low $5.99
- Market Cap $1,489,848,230
- Price Avg 50 EMA (D) $7.92
- Price Avg 200 EMA (D) $8.31
- Exchange NASDAQ
- Volume 5,733,284
- Average Volume 1,901,290
- Open $9.61
- Previous Close $9.29
- EPS -2.96
- PE -3.63
- Earnings Announcement 2025-02-26 10:59:00
- Shares Outstanding $138,590,533
Company brief: 89BIO, INC. (ETNB )
- Healthcare
- Biotechnology
- Mr. Rohan Palekar
- https://www.89bio.com
- US
- N/A
- 11-11-2019
- US2825591033
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.
ETNB Corporation News
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet
zacks.com -- The average of price targets set by Wall Street analysts indicates a potential upside of 219.1% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positiv...